# SPECIALTY GUIDELINE MANAGEMENT

# TRETTEN (coagulation Factor XIII A-Subunit [recombinant])

#### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### **FDA-Approved Indication**

Tretten is indicated in patients with congenital factor XIII A-subunit deficiency for routine prophylaxis for bleeding.

Tretten is not for use in patients with congenital factor XIII B-subunit deficiency.

All other indications are considered experimental/investigational and not medically necessary.

#### **II. CRITERIA FOR INITIAL APPROVAL**

### Congenital Factor XIII A-Subunit Deficiency

Authorization of 12 months may be granted for prophylactic treatment of congenital factor XIII A-subunit deficiency.

#### **III. CONTINUATION OF THERAPY**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when the member is experiencing benefit from therapy (e.g., reduced frequency or severity of bleeds).

## **IV. REFERENCES**

- 1. Tretten [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; June 2020.
- 2. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised August 2020. MASAC Document #263. https://www.hemophilia.org/sites/default/files/document/files/263\_treatment.pdf. Accessed November 20, 2020.

Tretten 2985-A SGM P2021.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2020 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of